Skip to content
VECTOR WIREAI INTELLIGENCE
UTC
Home

Isomorphic Labs raises $5B Series C to push AI-designed drugs toward clinic

$5B oversubscribed Series C co-led by Greenoaks and Sequoia, with Andreessen Horowitz joining.

Isomorphic Labs raised $5 billion in an oversubscribed Series C round announced on November 17, 2026, giving the Alphabet Inc.-backed AI drug-discovery company its third fundraise in roughly 20 months3,4.

Greenoaks and Sequoia co-led the round, joined by Andreessen Horowitz and several other new investors5. Alphabet made a further significant investment, and every existing backer returned: Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund2.

The Series C follows a $600 million raise in March 2025 and a $2.1 billion round in May, according to Bloomberg1.

ANALYSIS The pace and scale of the three rounds position Isomorphic Labs among the most heavily funded private companies applying AI to drug discovery.

Proceeds will fund further development of the company's proprietary drug-design engine, known as IsoDDE, which unifies a suite of foundational simulation AI models that work across multiple therapeutic areas and drug modalities. IsoDDE explores large chemical spaces to design, refine, and deliver molecules with optimal drug-like properties, according to the company.

Isomorphic Labs said its models and biological reasoning tools are producing positive preclinical results in internal oncology and immunology programs, as well as in partnered work, and that it is preparing to advance candidates toward clinical trials. The funding will also support expansion into new areas of biology, construction of global AI-led bioengineering infrastructure, and investment in translational and clinical-development capabilities. The company said it is building a partner ecosystem to improve understanding of disease biology.

ANALYSIS The central test for Isomorphic Labs remains whether preclinical progress generated by its AI platform translates into clinical evidence in human trials — a transition that has historically filtered out the majority of drug candidates regardless of how they were designed.

Was this useful?

The day’s vector, in your inbox.

Vector Wire Daily: one dispatch each publishing day.